Table 1 CAR-T-, mAbs- or BTCE-based therapies currently under clinical investigation for T-ALL treatment
Target | Type | Intervention/treatment | Identifier | Stage | Investigators/responsible party |
|---|---|---|---|---|---|
CD4 | CAR-T | Anti-CD4 CAR-T cells for the treatment of r/r T-cell leukemia and lymphoma | NCT03829540 | Phase 1 | Indiana University |
| Â | CAR-T | Anti-CD4 CAR-T cells designed to treat leukemia and lymphoma expressing CD4 antigen | NCT04162340 | Phase 1 | iCell Gene Therapeutics |
CD5 | CAR-T | Donor-derived CD5 CAR-T cells in patients with r/r T-ALL pre-treated with chemotherapy | NCT05032599 NCT05487495 | Phase 1 | Beijing Boren Hospital |
|  | CAR-T | CD5 chimeric receptor attached to CD28 from patient’s T cells or bone marrow transplant donor’s T cells for treatment of T-cell malignancies | NCT03081910 | Phase 1 | Baylor College of Medicine |
| Â | CAR-T | Anti-CD5 CAR-T cells for r/r T cell malignancies | NCT04594135 | Phase 1 | iCell Gene Therapeutics |
CD7 | CAR-T | Anti-CD7 CAR-T cells for the treatment of r/r acute leukemia | NCT04785833 | Not applicable | PersonGen BioTherapeutics (Suzhou) Co., Ltd |
| Â | CAR-T | Anti-CD7 CAR-T cells for the treatment of r/r T-ALL or T-LBL | NCT04572308 | Phase 1 | Hebei Senlang Biotechnology Inc., Ltd |
| Â | CAR-T | Anti-CD7 CAR-T cells for r/r T-cell malignancies | NCT05290155 | Phase 1 | Shanghai Jiao Tong University School of Medicine |
| Â | CAR-T | T-cell injection targeting CD7 chimeric antigen receptor for T-cell malignancies | NCT04480788 NCT04004637 | Phase 1 | PersonGen BioTherapeutics (Suzhou) Co., Ltd |
| Â | CAR-T | Non-gene edited anti-CD7 CAR-T cells for patients with r/r T-ALL or leukemia | NCT04934774 NCT05212584 | Phase 1 | iCell Gene Therapeutics |
| Â | CAR-T | Anti-CD7 CAR-T cell in pediatric and young adult patients with r/r T-ALL or T-LBL | NCT04860817 | Early Phase 1 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
| Â | CAR-T | Safety and clinical activity evaluations of allogeneic anti-CD7 CAR-T cells (ThisCART7) for patients with r/r T-cell malignancies | NCT05127135 | Phase 1 | Fundamenta Therapeutics, Ltd |
| Â | CAR-T | CD7 chimeric receptor attached with CD28 added to it to T cells for T-cell malignancies | NCT03690011 | Phase 1 | Baylor College of Medicine |
| Â | CAR-T | CAR-T cell therapy for patients with r/r T-ALL | NCT05043571 | Phase 1 | National University Hospital, Singapore |
| Â | CAR-T | Autologous CD7 CAR-T cells in therapy of high-risk acute T-cell leukemia/lymphoma | NCT04840875 | Phase 1 | Beijing Boren Hospital |
| Â | CAR-T | CD7 specific CAR gene-engineered T-cell for leukemia and lymphoma | NCT04033302 | Phase 1 | Shenzhen Geno-Immune Medical Institute |
| Â | CAR-T | Anti-CD7 allogeneic CAR-T cells safety and antitumor activity evaluations in patients with r/r T-ALL or LBL | NCT04984356 NCT05509855 | Phase 1/2 | Wugen, Inc |
| Â | CAR-T | Humanized CD7 CAR-T cells for r/r acute leukemia | NCT04762485 | Phase 1/2 | The First Affiliated Hospital of Soochow University |
| Â | CAR-T | Donor-derived CD7 CAR-T cells in patients with r/r T-cell leukemia/lymphoma; investigations on efficacy and safety | NCT04689659 | Phase 2 | Beijing Boren Hospital |
CD38 | mAb | Safety and efficacy evaluations of isatuximab SAR650984 in patients with T-ALL or T-LBL | NCT02999633 | Phase 2 | Sanofi |
| Â | mAb | Isatuximab combined with chemotherapy in pediatric patients with r/r T-ALL | NCT03860844 | Phase 2 | Sanofi |
| Â | mAb | Daratumumab in T-ALL young patients | NCT03384654 | Phase 2 | Janssen Research & Development, LLC |
| Â | mAb | Daratumumab-hyaluronidase for T-ALL patients with persistent MRD after treatment with chemotherapy | NCT05289687 | Phase 2 | Eastern Cooperative Oncology Group |
| Â | CAR-T | Humanized CD7 CAR-T cell therapy for r/r acute leukemia | NCT04762485 | Phase 1/2 | The First Affiliated Hospital of Soochow University |
| Â | BTCE | Safety and efficacy evaluation of XmAb18968 for patients with T-ALL, T-LBL and AML | NCT05038644 | Phase 1 | Medical College of Wisconsin |
CD52 | mAb | Investigation on efficacy and safety of alemtuzumab (Campath-1H) for patients with adult T-cell lymphoma | NCT00061048 | Phase 2 | National Cancer Institute, National Institutes of Health |
| Â | mAb | Association of alemtuzumab and fludarabine phosphate with low-dose total body irradiation before stem cell transplant for haematologic cancer | NCT00040846 NCT00118352 | Phase 2 | Fred Hutchinson Cancer Center |
CD194 | mAb | Mogamulizumab for r/r patients with T-cell malignancies | NCT04848064 | Phase 1 | Ohio State University Comprehensive Cancer Center |